Loading clinical trials...

COMPLETEDNCT04589728

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

This is an retrospective and prospective observational multinstitutional study to evaluate the impact on outcome of the combination of HMA plus venetoclax in AML patients unfit for intensive chemother...

Lead sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto•23 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 1

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890 · Acute Myeloid Leukemia

RECRUITINGPhase 1

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

NCT06197672 · Acute Myeloid Leukemia

RECRUITINGPhase 2

Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

NCT07425782 · Acute Myeloid Leukemia, Consolidation Therapy, and more

RECRUITINGPhase 3

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632 · Adult Acute Myeloid Leukemia

RECRUITINGPhase 1

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

NCT06138587 · Acute Myeloid Leukemia, Leukemia, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 8, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment202

Start dateFeb 2021

Last updatedJul 8, 2025

Condition

Acute Myeloid Leukemia

Locations shown

Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia

Bergamo

Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia

Bologna

Asst Degli Spedali Civili Di Brescia - Uo Ematologia

Brescia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 8, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Trial snapshot

Condition

Locations shown

For caregivers